DV
Dividend Vision

BGLC — BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp Common stock (BGLC)

Total return is -61.7% over the past 5.9 years, 210.5 points behind SPY at 148.8%. Its deepest 1-year drawdown was 78.0%.

BGLC is an equity fund focused on common stock of BioNexus Gene Lab Corp, launched in September 2020. The fund does not currently report a distribution rate or expense ratio, and distribution frequency information is not available. This stock-based fund may appeal to investors seeking exposure to the biotechnology and gene therapy sector, though potential investors should note the limited publicly available data on yield characteristics and fund costs.

BGLC key facts

Asset type
Stock
Asset class
Equity
Inception date
09/16/2020
Last close
$1.57
Market cap
$4,012,741
Average volume
2135.0
Beta
2.205
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.49